Charles River Laboratories International Inc. (CRL) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
Charles River Laboratories International Inc. (CRL) carries a Roarable Rating of C+ (Hold) with 67/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
How CRL Turns Every Dollar of Sales Into Real Bottom-Line Profit
Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory
| Fiscal Year | Revenue | Gross Margin | Op Margin | Net Profit | Free Cash Flow | ROIC % |
|---|---|---|---|---|---|---|
| FY 2025 | $4.02B | 44% | 0.6% | -$144.3M | $557.0M | 0.4% |
| FY 2024 | $4.05B | 44% | 5.6% | $22.2M | $552.3M | 3.5% |
| FY 2023 | $4.13B | 44% | 14.9% | $474.6M | $498.1M | 8.2% |
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring CRL)
- ✓Live walkthrough of CRL's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
CRL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -0.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on CRL today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for CRL. Explore sector supply chains on /butterfly.
CRL Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is Charles River Laboratories International Inc. (CRL)?
In FY 2025 (10-K), CRL converted $4.0B of revenue into a 44% gross margin, 0.6% operating margin, and $557.0M in free cash flow (13.9% FCF margin).